Apellis Pharmaceuticals has slashed its headcount by a quarter and culled its pipeline to save $300m, which will be put towards supporting the ongoing launch of its potential blockbuster eye therapy, Syfovre.
Syfovre (pegcetacoplan injection) became the first ever US Food and Drug Administration approved treatment for geographic atrophy (GA) in February...